sglt2 inhibitors vs glp 1 agonists or GLP-1 receptor as second-line therapy in | VHRM Frontiers | First-line treatment with
Description
GLP-1 has a short half-life of only two minutes, due to renal clearance and endogenous GLP-1 is degraded by the enzyme dipeptidyl peptidase IV (DPP-4) (2022)

In both studies, improvements in weight associated with improved quality of life parameters, physical function and cardiometabolic risk factors [47]

Mike Haney: So the clinical indication, as I understand it, for getting one of these drugs for the purpose of obesity is a BMI of 30, or a BMI of 27 with another condition like diabetes

PMC Alharbi SH, et al
30031-7/asset/bedae7b4-4f80-4686-b4c7-9c3f908ac1bd/main.assets/gr1.jpg)